Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Merck KGaA
  6. News
  7. Summary
    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 10/25 03:59:53 pm
204.05 EUR   +0.82%
10/22MERCK : Moody's Raises Merck KGaA's Rating to A3 on Improved Business Profile
MT
10/21MARKETMIND : Back to the blues
RE
10/20MERCK KGAA : Barclays takes a positive view
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : says lab supplies business can grow by up to 10% per year

09/09/2021 | 04:27am EDT
FILE PHOTO: A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt

FRANKFURT (Reuters) - Germany's Merck KGaA on Thursday issued a more ambitious medium-term growth forecast for its Life Science unit, as manufacturers of COVID-19 vaccines and treatments snap up its materials and gear.

Life Science division revenues are now expected to grow 7% to 10% per year until 2025, excluding the effect of currencies and acquisitions, significantly above market growth and higher than a previous goal of 6% to 9%, the diversified company said.

Pandemic-related demand would subside until 2025 but underlying demand for lab supplies would continue to be driven by the development of new biotech drugs and by China's ambitions to nurture an innovative pharmaceutical industry.

"Life Science will sharpen its focus on the Asia-Pacific region, especially China, as well as on innovations and digital solutions in all businesses," the company said in a statement on its capital markets day on Thursday.

The shares were up 2.4% at 0730 GMT, outperforming a 0.6% decline in the STOXX Europe 600 Health Care index.

Demand from the biotech industry has also fuelled the rise of Franco-German lab gear and supplies maker Sartorius, competing with Merck in complex equipment, to soon join Germany's blue-chip index DAX.

Family-controlled Merck said it expects group sales to grow organically by more than 6% per year on average through 2025, driven by demand for the Life Science unit's bioprocessing products, new pharmaceuticals and semiconductor chemicals.

That would lift 2025 group sales to about 25 billion euros ($30 billion), up from 17.5 billion in 2020.

Having reduced its debt from the 5.8 billion euro takeover of electronics materials maker Versum in 2019, Merck will now boost investments in plants and equipment and research and development through 2025 by more than half compared with the previous five years.

It will also have close to 10 billion euros to spend on acquisitions from the end of next year, though smaller and medium-sized deals are more likely.

The Life Science unit, mostly made up of businesses formerly known as Millipore and Sigma Aldrich, has surpassed the pharmaceuticals unit as Merck's main earnings driver, now accounting for about 45% of adjusted group earnings.

($1 = 0.8457 euros)

(Reporting by Ludwig Burger, editing by Thomas Escritt and Elaine Hardcastle)

By Ludwig Burger


ę Reuters 2021
All news about MERCK KGAA
10/22MERCK : Moody's Raises Merck KGaA's Rating to A3 on Improved Business Profile
MT
10/21MARKETMIND : Back to the blues
RE
10/20MERCK KGAA : Barclays takes a positive view
MD
10/20CytoReason Collaborates with Merck KGaA on Cancer Immunotherapy Drug
CI
10/20MARKETMIND : Margin pressures
RE
10/19MARKETMIND : Fast and furious
RE
10/14MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German Securities..
EQ
10/14MERCK : EMD Serono, Inc. - New Real-World MAVENCLAD Data Show Sustained Effectiveness and ..
AQ
10/13Merck KGaA's Multiple Sclerosis Treatment Drug Shows Improved Quality Of Life In Study
MT
10/13MERCK KGAA : JP Morgan reaffirms its Buy rating
MD
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Financials
Sales 2021 19 375 M 22 477 M 22 477 M
Net income 2021 2 765 M 3 208 M 3 208 M
Net Debt 2021 8 932 M 10 362 M 10 362 M
P/E ratio 2021 31,7x
Yield 2021 0,76%
Capitalization 88 347 M 103 B 102 B
EV / Sales 2021 5,02x
EV / Sales 2022 4,61x
Nbr of Employees 58 408
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 203,20 €
Average target price 200,03 €
Spread / Average Target -1,56%
EPS Revisions
Managers and Directors
BelÚn Garijo Lˇpez Chairman-Executive Board & CEO
Marcus Kuhnert Chief Financial Officer
Wolfgang Heinz BŘchele Chairman-Supervisory Board
Maria Rivas Chief Medical Officer & Senior Vice President
Laura Matz Chief Science & Technology Officer
Sector and Competitors